Effects of hypertonic saline, alternate day and daily rhDNase on healthcare use, costs and outcomes in children with cystic fibrosis

Suri, R; Grieve, R; Normand, C; Metcalfe, C; Thompson, S; Wallis, C; Bush, A; (2002) Effects of hypertonic saline, alternate day and daily rhDNase on healthcare use, costs and outcomes in children with cystic fibrosis. Thorax, 57 (10). pp. 841-6. ISSN 0040-6376 DOI: https://doi.org/10.1136/thorax.57.10.841

Full text not available from this repository.


BACKGROUND: Daily recombinant human deoxyribonuclease (rhDNase) is an established but expensive treatment in cystic fibrosis (CF). An alternative lower cost therapy is hypertonic saline (HS), which has been shown to improve lung function in short term studies. This study compares the costs and consequences of daily rhDNase with alternate day rhDNase and HS in children with CF. METHODS: In an open, randomised, crossover trial, 48 children with CF were allocated consecutively to 12 weeks of once daily 2.5 mg rhDNase, alternate day 2.5 mg rhDNase, and twice daily 5 ml 7% HS. Outcomes assessed included forced expiratory volume in 1 second (FEV(1)) and quality of life. All healthcare resource use was prospectively recorded for each patient. Unit costs were collected and combined with resource use data to give the total health service costs per patient for each treatment strategy. RESULTS: Daily rhDNase resulted in a significantly greater increase in mean FEV(1) than HS (8%, 95% CI 2 to 14) but there was no significant difference in FEV(1) between daily and alternate day rhDNase (2%, 95% CI -4 to 9). Over a 12 week period the mean incremental costs of daily rhDNase compared with HS was pound 1409 (95% CI pound 440 to pound 2318), and the incremental cost of using daily rather than alternate day rhDNase was pound 513 (95% CI - pound 546 to pound 1510). CONCLUSIONS: Daily rhDNase is more effective than 5 ml 7% HS twice daily delivered by jet nebuliser, but significantly increases healthcare costs. Administering rhDNase on an alternate day rather than a daily basis is as effective, with a potential for cost savings.

Item Type: Article
Keywords: Recombinant human dnase, human deoxyribonuclease, efficacy, therapy, safety, care, Adolescent, Child, Cystic Fibrosis, drug therapy, economics, physiopathology, Deoxyribonuclease I, economics, therapeutic use, Drug Administration Schedule, Drug Costs, Female, Forced Expiratory Volume, physiology, Health Care Costs, Health Resources, utilization, Human, Male, Prospective Studies, Saline Solution, Hypertonic, economics, therapeutic use, Sensitivity and Specificity, Support, Non-U.S. Gov't, Treatment Outcome
Faculty and Department: Faculty of Public Health and Policy > Dept of Health Services Research and Policy
PubMed ID: 12324668
Web of Science ID: 178534300002
URI: http://researchonline.lshtm.ac.uk/id/eprint/16839


Download activity - last 12 months
Downloads since deposit
Accesses by country - last 12 months
Accesses by referrer - last 12 months
Impact and interest
Additional statistics for this record are available via IRStats2

Actions (login required)

Edit Item Edit Item